NASDAQ:DMAA · NASDAQ Global Select
+$0.00 today
Vol 0.00M · Avg 0.11M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Management quality matters because capital allocation choices determine how much of Drugs Made In America Acquisition Corp. Ordinary Shares earnings power becomes long-term shareholder value. Use this page to compare DMAA returns on capital, executive context, insider transactions, ownership signals, and growth trends against peers, then decide whether leadership appears disciplined, aligned, and capable of compounding through changing market conditions.
Return Metrics
ROE, ROIC & ROA over time
ROE
2.6%
avg 99.4%
ROIC
-1.2%
avg -5.0%
ROA
2.5%
avg -42.2%
Analysis
ROE is currently the strongest return metric at 2.6% versus its period average of 99.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Roger Bendelac | Chief Executive Officer | — | — | 69 | — | — |
Saleem Elmasri | CFO & Principal Accounting Officer | — | — | 39 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A — |
| Revenue | N/A | N/A | N/A | N/A — |
| Net Income | N/A | N/A | N/A | N/A — |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Berto Acquisition Corp.
NASDAQ:TACO
$394.70M
Centurion Acquisition Corp.
NASDAQ:ALF
$391.36M
Berto Acquisition Corp. Unit
NASDAQ:TACOU
$378.32M
Titan Acquisition Corp.
NASDAQ:TACH
$360.18M
Oyster Enterprises II Acquisition Corp
NASDAQ:OYSE
$348.64M
SIM Acquisition Corp. I
NASDAQ:SIMA
$333.35M
Live Oak Acquisition Corp. V Class A Ordinary Shares
NASDAQ:LOKV
$331.20M
Renatus Tactical Acquisition Corp I Class A Ordinary Shares
NASDAQ:RTAC
$328.13M
Mountain Lake Acquisition Corp. Class A
NASDAQ:MLAC
$30.37M
Who manages DMAA?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) lists 2 active executives. The top listed executive is Roger Bendelac, Chief Executive Officer.
Are DMAA insiders buying or selling?
Recent insider activity shows net selling of $17.10M.
Explore More
Continue the stock analysis
Jump to another research area for this company.